CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Mesenchymal cellsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1040 vaccine candidate MVA-MERS-S Wiki 1.00
drug775 Standard of care Wiki 0.35

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Phase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19

The disease caused by the SARS-CoV-2 virus is a viral disease that infects the lungs, producing flu-like symptoms. Elderly infected patients and/or those with co-morbidities may suffer from acute respiratory distress syndrome due to pneumonia (COVID-19 disease). Given the high transmission, this virus has spread in recent months from Wuhan (China) to the whole world, becoming a global emergency pandemic. The lack of curative treatment for this disease justifies the need to carry out clinical trials that provide quality evidence on treatment options. Given the pathophysiology of the disease, which involves an uncontrolled inflammatory response of alveolar cells, a treatment that attenuates the cytokine cascade could be key in rescuing the patient's lung tissue. Mesenchymal cells, due to their immunoregulatory potential and regenerative capacity, can be an effective treatment for patients infected with the SARS-CoV-2 virus. In the present study we propose a therapy with undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue, a treatment whose safety has already been described in other clinical trials and that shows promising results in pilot studies carried out in China.

NCT04366271 COVID Biological: Mesenchymal cells Drug: Standard of care

Primary Outcomes

Description: Percentage of patients death due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment

Measure: Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment

Time: 28 days

Secondary Outcomes

Description: Percentage of patients death due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment

Measure: Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment

Time: 14 days

Description: Percentage of patients death due to any cause at 28 days of treatment

Measure: Mortality from any cause at 28 days

Time: 28 days

Description: Number of days without mechanical respirator and without vasopressor treatment for 28 days

Measure: Days without mechanical respirator and without vasopressor treatment for 28 days

Time: 28 days

Description: Percentage of patients alive without mechanical ventilation and without vasopressors on day 28

Measure: Patients alive without mechanical ventilation and without vasopressors on day 28

Time: 28 days

Description: Percentage of patients alive and without mechanical ventilation on day 14

Measure: Patients alive and without mechanical ventilation on day 14

Time: 14 days

Description: Percentage of patients alive and without mechanical ventilation on day 28

Measure: Patients alive and without mechanical ventilation on day 28

Time: 28 days

Description: Percentage of patients alive and without vasopressors on day 28

Measure: Patients alive and without vasopressors on day 28

Time: 28 days

Description: Number of days without vasopressors for 28 days

Measure: Days without vasopressors for 28 days

Time: 28 days

Description: Percentage of patients cured at 15 days

Measure: Patients cured at 15 days

Time: 15 days

Description: Percentage of patients with each adverse event

Measure: Incidence of Treatment-Emergent Adverse Events

Time: 1 year


No related HPO nodes (Using clinical trials)